Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.'s share was trading at $9.19 as of May 25th. VIR’s trailing P/E was 5.92 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. VIR is positioning itself as a potentially disruptive player in metastatic castration-resistant prostate cancer (mCRPC), an advanced and difficult-to-treat stage of prostate cancer with a five-year survival rate of roughly 30%. The company’s lead **** et, VIR-5500, is a PSMA-targeted T-cell engager designed to direct T-cells toward prostate cancer cells while minimizing the systemic toxicity that has limited competing therapies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Pressmaster/Shutterstock.com
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. VIR is positioning itself as a potentially disruptive player in metastatic castration-resistant prostate cancer (mCRPC), an advanced and difficult-to-treat stage of prostate cancer with a five-year survival rate of roughly 30%. The company’s lead **** et, VIR-5500, is a PSMA-targeted T-cell engager designed to direct T-cells toward prostate cancer cells while minimizing the systemic toxicity that has limited competing therapies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
5 months ago
